Bionano Genomics (BNGO) Total Liabilities (2017 - 2026)

Bionano Genomics' Total Liabilities history runs 10 years deep, the most recent figure standing at $27.3 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 9.54% year-over-year to $27.3 million; the TTM figure through Mar 2026 stood at $27.3 million (down 9.54% YoY), while the FY2025 annual figure was $29.2 million, down 29.39% from the prior year.
• Total Liabilities came in at $27.3 million for Q1 2026 at Bionano Genomics, down from $29.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $118.2 million in Q4 2023 to a low of $27.3 million in Q1 2026.
• A 5-year average of $48.4 million and a median of $41.3 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 236.45% in 2022 and tumbled 65.08% in 2024, its largest moves.
• Bionano Genomics' Total Liabilities stood at $58.1 million in 2022, then jumped by 103.51% to $118.2 million in 2023, then sank by 65.08% to $41.3 million in 2024, then decreased by 29.39% to $29.2 million in 2025, then fell by 6.24% to $27.3 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $27.3 million, $29.2 million, and $29.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison